374 related articles for article (PubMed ID: 30573773)
21. SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
Wei M; Zhang X; Wang X; Song Z; Ding J; Meng LH; Zhang A
Eur J Med Chem; 2017 Jan; 125():1156-1171. PubMed ID: 27846451
[TBL] [Abstract][Full Text] [Related]
22. CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia.
Montraveta A; Lee-Vergés E; Roldán J; Jiménez L; Cabezas S; Clot G; Pinyol M; Xargay-Torrent S; Rosich L; Arimany-Nardí C; Aymerich M; Villamor N; López-Guillermo A; Pérez-Galán P; Roué G; Pastor-Anglada M; Campo E; López-Guerra M; Colomer D
Oncotarget; 2016 Feb; 7(5):5507-20. PubMed ID: 26701728
[TBL] [Abstract][Full Text] [Related]
23. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells.
Modi P; Balakrishnan K; Yang Q; Wierda WG; Keating MJ; Gandhi V
Oncotarget; 2017 Mar; 8(10):16259-16274. PubMed ID: 28187444
[TBL] [Abstract][Full Text] [Related]
24. Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes.
Hofland T; de Weerdt I; Ter Burg H; de Boer R; Tannheimer S; Tonino SH; Kater AP; Eldering E
J Immunol; 2019 Oct; 203(8):2100-2109. PubMed ID: 31511358
[TBL] [Abstract][Full Text] [Related]
25. Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells.
Compagno M; Wang Q; Pighi C; Cheong TC; Meng FL; Poggio T; Yeap LS; Karaca E; Blasco RB; Langellotto F; Ambrogio C; Voena C; Wiestner A; Kasar SN; Brown JR; Sun J; Wu CJ; Gostissa M; Alt FW; Chiarle R
Nature; 2017 Feb; 542(7642):489-493. PubMed ID: 28199309
[TBL] [Abstract][Full Text] [Related]
26. PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis.
Carter MJ; Cox KL; Blakemore SJ; Turaj AH; Oldham RJ; Dahal LN; Tannheimer S; Forconi F; Packham G; Cragg MS
Leukemia; 2017 Jun; 31(6):1423-1433. PubMed ID: 27843137
[TBL] [Abstract][Full Text] [Related]
27. The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells.
Braun C; Schlaweck S; Daecke SN; Brossart P; Heine A
Cancer Immunol Immunother; 2021 Dec; 70(12):3693-3700. PubMed ID: 34173009
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.
Rivas JR; Liu Y; Alhakeem SS; Eckenrode JM; Marti F; Collard JP; Zhang Y; Shaaban KA; Muthusamy N; Hildebrandt GC; Fleischman RA; Chen L; Thorson JS; Leggas M; Bondada S
Leukemia; 2021 Nov; 35(11):3188-3200. PubMed ID: 33731852
[TBL] [Abstract][Full Text] [Related]
30. SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia.
Fan L; Wang C; Zhao L; Wang Z; Zhang X; Liu X; Cao L; Xu W; Li J
Neoplasia; 2020 Dec; 22(12):714-724. PubMed ID: 33142237
[TBL] [Abstract][Full Text] [Related]
31. PI3Kδ inhibitors for the treatment of cancer: a patent review (2015-present).
Feng Y; Cu X; Xin M
Expert Opin Ther Pat; 2019 Dec; 29(12):925-941. PubMed ID: 31670985
[No Abstract] [Full Text] [Related]
32. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
Hoellenriegel J; Meadows SA; Sivina M; Wierda WG; Kantarjian H; Keating MJ; Giese N; O'Brien S; Yu A; Miller LL; Lannutti BJ; Burger JA
Blood; 2011 Sep; 118(13):3603-12. PubMed ID: 21803855
[TBL] [Abstract][Full Text] [Related]
33. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.
McClanahan F; Riches JC; Miller S; Day WP; Kotsiou E; Neuberg D; Croce CM; Capasso M; Gribben JG
Blood; 2015 Jul; 126(2):212-21. PubMed ID: 25979947
[TBL] [Abstract][Full Text] [Related]
35. Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia.
Gadi D; Griffith A; Wang Z; Tyekucheva S; Rai V; Fernandes SM; Machado JH; Munugalavadla V; Lederer J; Brown JR
Br J Haematol; 2022 Apr; 197(2):207-211. PubMed ID: 35170759
[TBL] [Abstract][Full Text] [Related]
36. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Brown JR; Byrd JC; Coutre SE; Benson DM; Flinn IW; Wagner-Johnston ND; Spurgeon SE; Kahl BS; Bello C; Webb HK; Johnson DM; Peterman S; Li D; Jahn TM; Lannutti BJ; Ulrich RG; Yu AS; Miller LL; Furman RR
Blood; 2014 May; 123(22):3390-7. PubMed ID: 24615777
[TBL] [Abstract][Full Text] [Related]
37. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
Brown JR
Semin Oncol; 2016 Apr; 43(2):260-4. PubMed ID: 27040704
[TBL] [Abstract][Full Text] [Related]
38. PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.
Funk CR; Wang S; Chen KZ; Waller A; Sharma A; Edgar CL; Gupta VA; Chandrakasan S; Zoine JT; Fedanov A; Raikar SS; Koff JL; Flowers CR; Coma S; Pachter JA; Ravindranathan S; Spencer HT; Shanmugam M; Waller EK
Blood; 2022 Jan; 139(4):523-537. PubMed ID: 35084470
[TBL] [Abstract][Full Text] [Related]
39. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.
Dong S; Guinn D; Dubovsky JA; Zhong Y; Lehman A; Kutok J; Woyach JA; Byrd JC; Johnson AJ
Blood; 2014 Dec; 124(24):3583-6. PubMed ID: 25258342
[TBL] [Abstract][Full Text] [Related]
40. Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.
Ali AY; Wu X; Eissa N; Hou S; Ghia JE; Murooka TT; Banerji V; Johnston JB; Lin F; Gibson SB; Marshall AJ
Leukemia; 2018 Sep; 32(9):1958-1969. PubMed ID: 29479062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
